Pharmaceutical Consultant, Bangkok, Thailand.
J Transl Med. 2013 Jan 2;11:1. doi: 10.1186/1479-5876-11-1.
Thailand faces a significant burden in terms of treating and managing degenerative and chronic diseases. Moreover, incidences of rare diseases are rising. Many of these-such as diabetes, cancer, and inherited inborn metabolic diseases-have no definite treatments or cure. Meanwhile, advanced health biotechnology has been found, in principle, to be an effective solution for these health problems.
Qualitative approaches were employed to analyse the current situation and examine existing public policies related to advanced health biotechnologies in Thailand. The results of this analysis were then used to formulate policy recommendations.
Our research revealed that the system in Thailand in relation to advanced health biotechnologies is fragmented, with multiple unaddressed gaps, underfunding of research and development (R&D), and a lack of incentives for the private sector. In addition, there are no clear definitions of advanced health biotechnologies, and coverage pathways are absent. Meanwhile, false advertising and misinformation are prevalent, with no responsible bodies to actively and effectively provide appropriate information and education (I&E). The establishment of a specialised institution to fill the gaps in this area is warranted.
The development and implementation of a comprehensive national strategic plan related to advanced health biotechnologies, greater investment in R&D and I&E for all stakeholders, collaboration among agencies, harmonisation of reimbursement across public health schemes, and provision of targeted I&E are specifically recommended.
泰国在治疗和管理退行性和慢性疾病方面面临着巨大的负担。此外，罕见病的发病率也在上升。其中许多疾病，如糖尿病、癌症和遗传性先天性代谢疾病，目前尚无明确的治疗方法或治愈方法。与此同时，先进的健康生物技术已被发现，原则上是解决这些健康问题的有效方法。
采用定性方法分析泰国先进健康生物技术的现状，并审查相关的现有公共政策。然后，利用这些分析结果制定政策建议。
我们的研究表明，泰国在先进健康生物技术方面的制度是分散的，存在多个未解决的差距，研发（R&D）资金不足，私营部门缺乏激励措施。此外，先进健康生物技术没有明确的定义，也没有涵盖途径。同时，虚假广告和错误信息很普遍，没有负责机构积极有效地提供适当的信息和教育（I&E）。有必要建立一个专门的机构来填补这一领域的空白。
建议制定和实施与先进健康生物技术相关的综合国家战略计划，增加对所有利益相关者的研发和 I&E 的投资，机构之间的合作，协调公共卫生计划的报销，以及提供有针对性的 I&E。
